Surprisingly, we found that ezetimibe, an approved drug for the treatment of hypercholesterolemia, prevented the upregulation of 4R-tau isoform transcripts induced by annonacin, and kept the ratio of 4R-/3R-tau isoforms similar to healthy control cells. The gene discussed is MAPT; the disease is familial hypercholesterolemia.